porno izle
porno
asyabahis
women desperate to piss ava addams mom porn sa akin ang gabi
sisli escort mecidiyekoy escort
replica watches
Neodyum Miknatis
implant
porno

Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



From the category archives: OBN News

Member Company Press Release

Vaccitech receives government grant for COVID-19 vaccine research

Oxford, UK: Vaccitech Limited, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has received a non-dilutive Government grant to support research with its next-generation technology platform to protect against COVID-19. The grant is part of the UKRI-NIHR COVID-19 rapid response rolling call for proposals with potential to deliver public health impacts within 12 months. Preclinical data indicate Vaccitech’s new platform induces leading antibody and cell-mediated immune responses, two arms of the immune system known to protect against disease, when compared with the adenoviral platforms currently in vaccine trials for COVID-19. The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech’s research efforts. Vaccitech was awarded £1 ...

Read the rest of entry »

Oxford Nanopore: Nanopore sequencing 101 - online seminar series is back!

The first in the series will be hosted by James Brayer — Associate Director, Market Development, Oxford Nanopore Technologies — on 8th September at 5pm (BST). Join James for an introduction to nanopore sequencing and be sure to bring your questions along for a Q&A which will follow the presentation.

Registration link

AMSBIO: New Cytometry Service Provides Automated Analysis of Fluorescent Biomarkers

AMSBIO announce a new service designed to provide high-content cytometry data on cells and tissues enabling the automated analysis of fluorescent biomarkers on living cells or long-term stored biobanked cells and tissues.  Leveraging the innovative ChipCytometry platform, AMSBIO is able to offer a complete workflow solution (products and services) for high-content cytometry on cells and tissues, from sample preparation and biobanking to biomarker analysis and data mining. The ChipCytometry platform operates by immobilizing cells in microfluidic chips, which are later stained with antibodies for multiplex biomarker detection. Using the ChipCytometry platform - AMSBIO can offer quantitative analysis of a virtually unlimited number of protein biomarkers in a single sample. AMSBIO is also to offer custom assays facilitating analysis of almost any antibody / biomarker target. Not only can this technology deliver quantitative biomarker analysis but it ca ...

Read the rest of entry »

Quotient: The Role of Biopharmaceutics in Early Drug Development - Webinar 6th October

Overcoming challenges for small molecules - webinar Nominated candidates entering clinical development often have sub-optimal physicochemical, biopharmaceutic or DMPK properties for oral delivery. Development teams are challenged with how to understand the properties of new drug candidates, how to design the appropriate formulation strategy and how to move quickly and successfully into early phase clinical trials. Along the way, it is important to identify developability risks and take steps to mitigate these factors, balanced carefully against time and cost investments. This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan. Speakers: Dr Vanessa Zann, Senior Drug Development Consultant, Quotient Sciences Dr Shriram Pathak, Senior Research Fellow, Scientific ...

Read the rest of entry »

Isansys’ Patient Status Engine named among top 10 healthcare innovations in fight against Covid-19

Oxford, UK: In the Times Future of Healthcare supplement, Isansys’ Patient Status Engine (PSE), a smart clinical data collection, analysis and prediction platform, was acclaimed for playing a crucial role in helping care teams around the world combat the Coronavirus. Using real-time patient data to track the course of the disease, the unique clinical infrastructure aims to improve early detection of Covid-19 – and many other conditions – in patients in hospital and home settings. The PSE uses wearable body-worn sensors to continuously and wirelessly monitor vital signs including heart rate, ECG patterns, respiration rate, blood pressure, temperature and oxygen saturation. Advanced analytic techniques can use these high resolution and highly correlated physiological signals to indicate the presence of the virus, potentially before symptoms are detectable by other methods. These digital biomarkers provide a valuable stream of health data which can enable care teams to better unders ...

Read the rest of entry »

ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-19

Foster City, Calif., and Nottingham, UK:  ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials. Laboratory experiments have shown niclosamide stops SARS-CoV-2 (the virus that causes COVID-19) from replicating, making it a promising candidate for reducing the spread of COVID-19. Niclosamide was previously approved by the FDA as a treatment for tapeworm and although not currently marketed in the U.S., it is on the World Health Organization’s List of Essential Medicines and has been used for decades to ...

Read the rest of entry »

Discovery Park receives £2.5m of Government funding to accelerate delivery of Incubator

Sandwich, Kent, UK:  Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, has been awarded £2.5m towards accelerated delivery of its Incubator facility by the South East Local Enterprise Partnership (SELEP). The grant, which comes from SELEP’s £85m share of the Government’s new Getting Building Fund, will be used to create flexible laboratory, write-up and office space for innovative SMEs. Discovery Park’s investors are committing £3m to this development, which is expected to be completed by the middle of next year. A masterplan has been created for the Incubator space and initial design works completed. The 50,000 sq ft of laboratory and write-up space will be created on two floors of the East Block of the Park’s Building 500. The new Incubator facility will be suitable for all types of start-ups and early stage companies, including drug discovery, cell and gene therapy, digital health, manufacturing a ...

Read the rest of entry »

VivoPlex Clinical Stage funding round brings £3.9m for product development

  Oxford, UK:  VivoPlex Group Ltd, which is transforming fertility treatment and women’s health via intra-uterine sensing, has raised £3.9m in its Clinical Stage financing round. The funds, which were raised in two tranches, will be used to complete the first clinical feasibility study of its wireless battery-free uterine sensor system. The study is expected to generate key clinical data to support European approval (CE marking) for the company’s first product.   The Future Fund participated in the second tranche of the fundraising alongside other investors, unlocking matched financing and helping to drive the business forward towards commercialisation. Developed by the Government and delivered by the British Business Bank, the Future Fund supports high potential innovative businesses in the UK currently affected by Covid-19.   In line with other medical device and pharmaceutical companies, the clinical feasibility study will start as soon as practicabl ...

Read the rest of entry »

Leaf Expression Systems Appoints Dr. Leanne Williams as its Business Development Manager

Norwich, UK: Leaf Expression Systems (Leaf), a contract development and manufacturing organisation specialising in plant-based expression of proteins, vaccines, enzymes and complex natural products, is pleased to announce the recent appointment of Dr. Leanne Williams as Business Development Manager. Leanne has over 10 years’ experience working in the life sciences industry in both commercial and academic settings and will lead the growth of Leaf’s pipeline by identifying and establishing commercial collaborations within the global life science industry.

Read the rest of entry »

University of Birmingham spinout announces collaboration and licence agreement to develop precision cancer treatments

University of Birmingham spinout Revitope Oncology Inc has announced a research collaboration and licence agreement with leading Chinese biopharmaceutical company Junshi Biosciences to develop precision cancer therapies that harness the body’s immune response to kill cancer cells while leaving healthy body tissues untouched. Revitope will leverage its proprietary protein engineering platform with Junshi’s novel antibody components to develop first-in-class dual antigen targeting cancer therapies.   Revitope will receive up to $160 million per molecule in milestones and royalties on net sales of 10%.  Junshi has also committed to acquire a 9.99% stake in Revitope for $10 million. Revitope’s technology, known as the T-cell engager antibody circuit (TEAC), has the potential to significantly improve outcomes for millions of cancer patients.  The technology splits antibodies into two halves which are programmed to recognise different antigens.  The two halves ...

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.